510(k) Report

510(k) · Cleared

Cleared

Unigold Giardia

K120001510(k) TraditionalCleared Mar 1, 2013423-day reviewClass II21 CFR 866.3220

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Trinity Biotech · MHI Giardia Spp.

Cleared on Mar 1, 2013 as substantially equivalent to K031942 (Remel, Inc., 2003) after a 423-day review. Its family tree reaches back 2 generations to 1999.

Decided
Mar 1, 2013
Review
423 days
Class
Class II
Product code
MHI
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K983399 (1999). No later device cites it as a predicate yet.

  1. Root · 2 generations backK983399 Giardia/Cryptosporidium Combo Rapid AssayGenzyme Diagnostics · 1999 · Recalled
  2. 1 generation backK031942 Xpect Giardia Lateral Flow Assay, Model 2450020Remel, Inc. · 2003
  3. This deviceK120001 Unigold GiardiaTrinity Biotech · 2013
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K983399Giardia/Cryptosporidium Combo Rapid AssayGenzyme Diagnostics19992
−1K031942Xpect Giardia Lateral Flow Assay, Model 2450020Remel, Inc.2003—
0 (this device)K120001Unigold GiardiaTrinity Biotech2013—
FIG. 1 — Lineage of K120001, 1999–2013Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MHI? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K031942Xpect Giardia Lateral Flow Assay, Model 2450020
Summary page 1
…ction with the clinical evaluation and medical history. For In-Vitro Diagnostic use. Drevice Remel Xpectm Giardia Lateral Flow Assay (51OK #: K031942) 5919 Farnsworth Court aCarlsbad, California 92008 USA . 760-929-0500 - Fax: 760-929-0124…
Remel, Inc.2003—

Also cleared against K031942: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 14 years and passes through 3 companies; a new generation was cleared every 9.3 years on median.
  • 1 of the 2 ancestors has a recall of any class.
  • 1 other device also cites its predicate K031942.

How does its category compare?

All MHI devices

MHI Giardia Spp.: FDA decisions, review times, recalls and adverse event reports over 20 years. 2013, this device’s year, is highlighted.

FDA decisions per year · MHI

1in 2013

2009: 12011: 12013: 1
2007high 1 (2009) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MHI

Too few MHI 510(k)s in any year since 2007 to give a median.

Recalls per year · MHI

1in 2025

2008: 12025: 1
2007high 1 (2008) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · MHI

No MAUDE report names MHI since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—10
20091—00
20100—00
20111—00
20120—00
20131—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20210—00
20220—00
20230—00
20240—00
20250—10
20260—0—

What is it indicated for?

Trinity Biotech Uni-Gold Tm Giardia is a single use rapid immunoassay for the qualitative detection of Giardia lamblia (G. lamblia) antigens in human stool specimens. This test is intended for use with patients with gastrointestinal symptoms as an aid in the diagnosis of suspected Giardia gastrointestinal infections. As with other Giardia tests, results should be considered in conjunction with the clinical evaluation and medical history. For In-Vitro Diagnostic use.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K120001: Unigold Giardia.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K120001

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026